Enodia Therapeutics Names Dr. Yvonne McGrath as CSO to Advance Targeted Protein Degradation Platform
Enodia Therapeutics Appoints Dr. Yvonne McGrath as Chief Scientific Officer to Accelerate Upstream Targeted Protein Degradation Platform Enodia Therapeutics, a biotechnology company developing small-molecule therapies targeting a unique form of…
Quanterix Unveils Content Innovation Engine at AACR 2026
Quanterix Debuts Content Innovation Engine at AACR 2026 Quanterix Corporation today announced plans to debut its Content Innovation Engine at the American Association for Cancer Research (AACR) Annual Meeting 2026.…
ClearNote Health Highlights Avantect® Pancreatic Cancer Test Performance at AACR 2026
ClearNote Health to Showcase Industry-Leading Early Detection Performance of the Avantect® Pancreatic Cancer Test at AACR Annual Meeting 2026 ClearNote Health, a company dedicated to improving early detection for some…
LEO Pharma Secures FDA Acceptance of sNDA for ANZUPGO® Cream in Adolescent Hand Eczema
LEO Pharma Announces FDA Acceptance of Supplemental NDA for ANZUPGO® (delgocitinib) Cream for the Treatment of Chronic Hand Eczema in Children Aged 12-17 LEO Pharma Inc., a global leader in…
Forlong Biotechnology Achieves CMC Readiness for GMP Production of FL115 Ahead of Pivotal NMIBC Trial
Forlong Biotechnology Announced CMC Readiness to Initiate GMP Batch Production to Support Upcoming Pivotal Clinical Trial for FL115 (IL-15 Superagonist) in Nonmuscle Invasive Bladder Cancer (NMIBC) Forlong Biotechnology, a clinical-stage…
Revolution Medicines Prices $2 Billion in Upsized Concurrent Offerings of Stock and Convertible Senior Notes
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with…
Astellas Initiates Phase 3 Trial of Setidegrasib (ASP3082) in KRAS G12D-Mutated Metastatic Pancreatic Cancer, Dosing First Patient
Astellas Doses First Patient in Phase 3 Study of setidegrasib (ASP3082) for KRAS G12D-mutated Metastatic Pancreatic Ductal Adenocarcinoma Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that…
Erin Lichy Opens Up About Her Natrelle® Breast Augmentation Experience
Erin Lichy Gets Real About Her Natrelle® Breast Augmentation Allergan Aesthetics, an AbbVie company (NYSE: ABBV) has teamed up with New York-based entrepreneur and television personality, Erin Lichy. Lichy is…
First Patients Receive Cabaletta Bio’s Rese-cel Produced Using Cellares’ Automated Cell Shuttle™ Platform
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares’ Automated Cell Shuttle™ Platform Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.’s (“Cabaletta…
Imperative Care Launches ADAPT 2.0 Study to Assess Streamlined Technique for Acute Ischemic Stroke Treatment
Imperative Care Initiates ADAPT 2.0 Study Evaluating Advanced Clinical Technique Designed to Simplify Acute Ischemic Stroke Treatment Imperative Care, a medical technology company focused on advancing treatments for patients suffering…
Sutter Health Broadens Use of Wearable Ultrasound Technology Across Bay Area Hospitals to Enhance Sepsis Care
Sutter Health Expands Use of Wearable Ultrasound Tech Across Additional Bay Area Hospitals to Advance Sepsis Care Sutter Health is expanding the use of FloPatch, the first wireless, wearable Doppler…
VectorBuilder Launches High-Stability MuteFree™ AAV to Enhance Gene Therapy Manufacturing Reliability
VectorBuilder Introduces High-Stability MuteFree™ AAV to Improve Gene Therapy Manufacturing Reliability VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree™ AAV, a high-stability AAV vector…